LGALS3 and non-small cell lung carcinoma: Clinical phase 1/2 trial: Investigation of the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC)